Insider Transactions in Q4 2022 at Ligand Pharmaceuticals Inc (LGND)
Insider Transaction List (Q4 2022)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 30
2022
|
Octavio Espinoza Chief Financial Officer |
BUY
Other acquisition or disposition
|
Direct |
275
+1.43%
|
$15,400
$56.78 P/Share
|
|
Dec 28
2022
|
John L Higgins Director |
SELL
Payment of exercise price or tax liability
|
Direct |
5,289
-1.25%
|
$349,074
$66.29 P/Share
|
|
Dec 28
2022
|
Matthew E Korenberg President & COO |
SELL
Payment of exercise price or tax liability
|
Direct |
3,859
-4.0%
|
$254,694
$66.29 P/Share
|
|
Dec 16
2022
|
John L Higgins Director |
SELL
Open market or private sale
|
Direct |
10,000
-2.31%
|
$610,000
$61.87 P/Share
|
|
Dec 13
2022
|
Matthew E Korenberg President & COO |
BUY
Grant, award, or other acquisition
|
Direct |
14,000
+12.68%
|
-
|
|
Dec 13
2022
|
Octavio Espinoza Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
11,000
+37.07%
|
-
|
|
Dec 12
2022
|
John L Higgins Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
3,944
-0.9%
|
$252,416
$64.8 P/Share
|
|
Dec 12
2022
|
John L Higgins Director |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+4.38%
|
$240,000
$12.78 P/Share
|
|
Nov 30
2022
|
Andrew Reardon CLO & Secretary |
SELL
Payment of exercise price or tax liability
|
Direct |
1,073
-8.93%
|
$77,256
$72.9 P/Share
|
|
Nov 30
2022
|
Octavio Espinoza Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,187
-13.4%
|
$85,464
$72.9 P/Share
|
|
Nov 30
2022
|
John L Higgins Director |
SELL
Payment of exercise price or tax liability
|
Direct |
9,803
-2.3%
|
$705,816
$72.9 P/Share
|
|
Nov 30
2022
|
Matthew E Korenberg President & COO |
SELL
Payment of exercise price or tax liability
|
Direct |
3,593
-4.18%
|
$258,696
$72.9 P/Share
|
|
Nov 18
2022
|
John L Higgins Director |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+2.29%
|
$120,000
$12.78 P/Share
|
|
Nov 17
2022
|
John L Higgins Director |
SELL
Open market or private sale
|
Direct |
10,000
-2.34%
|
$780,000
$78.32 P/Share
|
|
Nov 09
2022
|
Octavio Espinoza Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,696
-16.07%
|
$127,200
$75.64 P/Share
|
|
Nov 01
2022
|
John L Higgins Director |
BUY
Grant, award, or other acquisition
|
Direct |
45,922
+9.76%
|
-
|
|
Nov 01
2022
|
Sarah Boyce |
SELL
Sale (or disposition) back to the issuer
|
Direct |
1,004
-25.77%
|
-
|
|
Nov 01
2022
|
Matthew W Foehr |
SELL
Sale (or disposition) back to the issuer
|
Direct |
20,304
-11.13%
|
-
|
|
Nov 01
2022
|
Charles S Berkman |
SELL
Sale (or disposition) back to the issuer
|
Direct |
11,944
-33.39%
|
-
|
|
Nov 01
2022
|
Sunil Patel |
SELL
Sale (or disposition) back to the issuer
|
Direct |
1,004
-3.37%
|
-
|
|
Nov 01
2022
|
Jennifer R. Cochran |
SELL
Sale (or disposition) back to the issuer
|
Direct |
1,004
-46.37%
|
-
|
|
Nov 01
2022
|
Matthew E Korenberg President & COO |
BUY
Grant, award, or other acquisition
|
Direct |
27,714
+24.37%
|
-
|